HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Light at end of the tunnel?

This article was originally published in The Rose Sheet

Executive Summary

Market research firm has good news and bad news regarding consumer attitudes in the current economy. On NPD's Economy Tracker scale of 0 ("Very Concerned") to 100 ("Very Confident"), consumers' "general economic perception" score has dropped from 38 in October to 36.7 in February. With that drop of less than two points, consumers' intention to spend has fallen more than 5 points, NPD notes. However, consumer concern for job security appears to be leveling off - with 34% "very concerned" about job security and/or income in February, versus 36% the month before and 38% in December - "which could mean they are preparing to spend again," firm says. Marshal Cohen, chief industry analyst at NPD, states: "Of all the data I look at, this measure provides one of the best indications of how consumers are going to behave. February's results show consumers feeling better on this front and could signal consumer stabilization, a point at which consumers catch their breath, reassess and prioritize their purchase needs in preparation to begin spending again." NPD's Economy Tracker delivers monthly reports and a year-end analysis based on online surveys completed by consumers nationwide

You may also be interested in...



US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market

Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel